Cytheris Announces Publication Of IL-7 HIV Data In The Journal Of Clinical Investigation

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, announced the publication of data from a multi-center Phase I/IIa study designed to investigate the safety of Interleukin-7 (IL-7) therapy in chronically HIV-1 infected patients whose CD4 T cell counts remained low despite treatment with anti-retroviral-therapies (HAART).